International Reporting Mechanism for Unethical Germline Gene Editing Experiments Is Needed
By G. Owen Schaefer, Markus K. Labude, Yujia Zhu, Roger Sik-Yin Foo, Vicki Xafis,
Trends in Biotechnology
| 11. 04. 2020
The 2018 revelation of the birth of the first babies whose DNA had been edited shocked the world and was met almost instantly with condemnation from scientists, ethicists, and policymakers around the world [1] (Box 1). The news was not a shock to quite everyone, however. A recent article reveals that a large number of individuals around the world knew about the experiment, in one form or another, before the news broke internationally [2]. He Jiankui, who led the experiment, had built up an international network of collaborators for several of his biotechnology ventures and at various stages communicated progress of his experiment to international colleagues. Some now say they tried to discourage him, but none made known the ongoing experiment to the broader international community.
In this article, we argue that revealing such activities is in line with scientists’ responsibilities to uphold the integrity and trustworthiness of the scientific enterprise. However, the international context complicates the situation; it is not clear whom individuals who knew about the experiment should have approached. To fill...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
By Briana Contreras, Managed Healthcare Executive | 06.17.2025